Loading clinical trials...

REQUIP RLS Post Marketing Surveillance | Clinical Trials | Clareo Health

COMPLETED

REQUIP RLS Post Marketing Surveillance

An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information

NCT01327339•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS

Detailed Description

This study is a post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS(restless leg syndrome) and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of ropinirole in real clinical practices after marketing. The subjects are patients prescribed for ropinirole by the investigators at the sites based on prescription information in normal clinical practices.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects diagnosed with RLS by the investigator
•Subjects who the investigator believes that they can and will comply with the requirements of the protocol
•* To be contactable over the phone
•* To follow the administration regimen.
•A male or female aged 18 years and more at the time of the first prescription.
•Subjects with no experience of RLS treatment using ropinirole

Exclusion Criteria

•Subjects with hypersensitivity to ropinirole and any excipients
•Female who is during the period of the pregnancy or who are lactating

Key Dates

Start Date

April 1, 2006

Primary Completion Date

November 30, 2009

Completion Date

November 30, 2009

Last Updated

September 12, 2017

Enrollment

755

ACTUAL participants

Conditions

Restless Legs Syndrome

Interventions

Ropinirole

DRUG

Functional Connectivity of the Interoceptive Network in RLS

NCT07001891

Restless Legs Syndrome

View study

RECRUITINGNA

The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With Motoneuron Hyperexcitability

NCT05908214

StrokeCramp+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

REQUIP RLS Post Marketing Surveillance

Inclusion Criteria

Exclusion Criteria

Functional Connectivity of the Interoceptive Network in RLS

The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With Motoneuron Hyperexcitability

Quality Improvement and Practice Based Research in Neurology Using the EMR

A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS

Adverse Long-term Consequences of Sleep Disordered Breathing: The Ottawa Hospital (TOH) Sleep Database

Impact of Iron Supplementation Treatment on Brain Iron Concentrations